Vanguard Global Advisers
KPTI icon

Vanguard Global Advisers’s Karyopharm Therapeutics KPTI Stock Holding History

Vanguard Global Advisers’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.2K Hold
8,207
– – ﹤0.01% 2878
2026
Q1 		$45.7K Buy
+8,207
New +$62.6K ﹤0.01% 3063

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Global Advisers's KPTI Position: Q2 2026 in Review

Vanguard Global Advisers held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 8,207 shares worth $80.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

Vanguard Global Advisers first reported a position in KPTI in Q1 2026 and has held it in 2 quarters since. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Vanguard Global Advisers held 8,207 shares of Karyopharm Therapeutics worth $80.2K as of Q2 2026.
  • Vanguard Global Advisers left its Karyopharm Therapeutics share count unchanged in Q2 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2878 holding.
  • Vanguard Global Advisers first reported a position in Karyopharm Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.